SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) announced on September 16, 2025 a board resolution to launch an initiative to develop quantum-powered 3D protein modeling for drug discovery, with a focus on neurological and rare diseases.

The program will form a dedicated research team, create a wholly owned Israeli subsidiary, collaborate with experts in quantum computing and structural biology, refine quantum algorithms for protein folding and protein-ligand interactions, and seek new intellectual property.

Insights

Computational drug-discovery analyst

SciSparc launched a quantum-enabled 3D protein modeling initiative to support drug discovery, starting with a new Israeli subsidiary and collaborations announced in October 23, 2025.

The company plans to build a dedicated research team and create intellectual property by integrating quantum computing algorithms with 3D protein folding and protein–ligand interaction modeling. The program targets applications in neurological and rare diseases and will begin under a newly formed wholly owned Israeli subsidiary; the board resolved to initiate the work on September 16, 2025.

Technical feasibility and near-term commercial impact remain uncertain because the content describes aims and program structure rather than validated results or funding details. Key dependencies include successful collaboration with quantum and structural-biology experts, access to quantum hardware or high-fidelity simulators, and demonstrable algorithmic advances. Monitor milestones such as prototype algorithm performance, any disclosed computational benchmarks versus classical methods, collaboration agreements, and the timeline for the subsidiary's formal incorporation over the next 6–24 months.

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, recently announced that on September 16, 2025 the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”). This new program aims to transform drug discovery by potentially achieving unprecedented accuracy in predicting protein structures and interactions with their ligands, potentially paving the way for breakthroughs in structural biology and personalized medicine.

Proteins are the building blocks of life and their function often depends on their unique 3D shapes. Knowing a protein’s 3D structure is critical for understanding how it interacts in the body, how to treat a related disease and how to design effective drugs using the highest possible level of accuracy. Traditionally, scientists use computers to predict these 3D structures, but this process is challenging because proteins are dynamic, constantly shifting between different conformations and classical computers often struggle to model these changes accurately.

SciSparc’s new Initiative aims to leverage quantum computing, a cutting-edge technology that uses principles of quantum mechanics to perform calculations far beyond the capabilities of traditional computers. Unlike classical computing methods, quantum computing might simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with their ligands in a much higher accuracy. This initiative focuses on developing quantum-enabled tools to:

• accurately predict how proteins fold into their 3D shapes;
• model how proteins interact with potential drugs (protein-ligand interactions); and
• accelerate the discovery of new drugs by providing highly precise predictions.

SciSparc will form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling with the aim of creating new intellectual property. The Company will collaborate with leading experts in quantum computing and structural biology to build these capabilities. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, targeting applications in drug discovery for neurological and rare diseases, areas where SciSparc already has expertise. SciSparc expects to incorporate a new wholly owned Israeli subsidiary which will operate the Initiative.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority owned subsidiary Neurothera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through Neurothera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses: the successful launch of the Initiative, that the Company will form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling;  the potential benefits and advantages of the new Initiative regarding AI drug discovery; collaborating with leading experts in quantum computing and structural biology; the incorporation of a new subsidiary to operate the Initiative and that the Company’s initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions.. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972 3-761-7108

FAQ

What did SciSparc (SPRC) announce on September 16, 2025 about quantum 3D protein modeling?

The board resolved to launch an initiative to develop quantum-enabled 3D protein modeling tools targeting protein folding and protein-ligand interactions for drug discovery.

How will SciSparc (SPRC) structure the quantum protein modeling initiative and where will it operate?

SciSparc plans a dedicated research team and to incorporate a wholly owned Israeli subsidiary to operate the Initiative.

Which therapeutic areas will SciSparc (SPRC) target with its quantum modeling effort?

Initial efforts will target drug discovery applications for neurological and rare diseases, areas where SciSparc has existing expertise.

Will SciSparc (SPRC) form partnerships for the quantum protein modeling Initiative?

Yes; the company said it will collaborate with leading experts in quantum computing and structural biology to build capabilities and IP.

What technical goals did SciSparc (SPRC) set for the quantum program?

Goals include accurately predicting protein 3D folding, modeling protein-ligand interactions, and accelerating drug discovery through refined quantum algorithms.